Generic Name and Formulations:
Naloxone HCl 0.4mg/0.4mL, 2mg/0.4mL; soln in a prefilled auto-injector for IM or SC inj; latex-free.
Indications for EVZIO:
Emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or CNS depression.
Adults and Children:
<1yr: Pinch thigh muscle while administering; monitor inj site for residual needle parts and/or infection. ≥1yr: Inject IM or SC into the anterolateral aspect of the thigh (through clothing, if necessary) according to label instructions. All: may give additional doses every 2–3 mins until desired response or emergency medical assistance available. Repeated doses depending on amount, type, and route of administration of the opioid being antagonized may be required.
Not a substitute for emergency medical care. Monitor patients with satisfactory response due to long duration of some narcotics. Have other resuscitative measures available. Known or suspected opioid dependence; abrupt reversal may precipitate acute withdrawal syndrome. Post-op use in pre-existing cardiac disorders; monitor. Neonates. Elderly. Pregnancy. Nursing mothers.
Caution with cardiotoxic drugs. Incomplete reversal of mixed agonists/antagonists (eg, buprenorphine, pentazocine); may require higher naloxone dose.
Dizziness, inj site erythema; precipitation of severe opioid withdrawal.
Prefilled auto-injectors—2 (w. Trainer)
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL